Based on the core talent team at home and abroad, Annoyouda has its own leading genome sequencing and bioinformatics technology, established a leading high-throughput sequencing platform and high-performance computing platform, and has reached a goal with American Illumina and Alibaba Cloud. Strategic cooperation has formed a strong Bio-IT infrastructure and industrial service capabilities. In terms of technology, never stop the pace of innovation in research and development!
Recently, the State Food and Drug Administration (CFDA) approved the NextSeq 550AR gene sequencing instrument produced by Annoyoda Gene Technology, and the detection kit for fetal chromosome aneuploidy (T21, T18, T13) (reversible end termination sequencing) ) Medical device product registration.
NextSeq 550AR
NextSeq 550AR Gene Sequencer is a new generation of desktop high-throughput gene sequencer developed by Annoyouda and Illumina in the United States. It is solely invested and developed by Annoyouda in China, application development and registration. The equipment is also currently The most advanced model of the global clinical gene sequencer. The device uses Illumina's newly developed dual-channel "Synthesis Side Sequencing (SBS)" technology and the classic "Reversible Terminal Terminator" patented technology, which also reflects the deep technical accumulation of Annoyouda in clinical transformation and domestic The deep understanding of clinical habits, with high throughput, fast speed, accurate data, stable performance, simple operation and many other advantages, is bound to provide more advanced solutions for the clinical application market. Compared with the existing equipment in the market, its data quality, stability and batch sample processing capabilities all have significant leading advantages. At the same time, NextSeq 550AR has strong clinical and academic application scalability, including PGS, liquid biopsy, FFPE sequencing, genetic disease detection, etc. The kit can be developed and registered on this sequencing platform.
At the same time, Annoyoda's non-invasive prenatal DNA test (NIPT) kit, the fetal chromosome aneuploidy (T21, T18, T13) test kit (reversible end-stop sequencing) was also approved by the CFDA. It can detect up to 96 NIPT clinical samples and achieve a great breakthrough in data quality and data yield. The data quality is Q30>93% and the highest data yield is 120G.
Dr. Chen Reconstruction, CEO of Annoyouda
Dr. Chen Reconstruction said, “Non-invasive prenatal DNA testing has opened up a new era of prenatal testing. Annoyouda is one of the earliest companies in China to develop clinical applications of this technology. As the first batch of clinical pilot units in the country, we have promoted and witnessed The rapid development and clinical popularization of this technology. After 4-5 years of development, the application of non-invasive prenatal DNA detection in the field of reproductive health has been deeply rooted in the hearts of the people, and has also received positive evaluation from national policies and markets. At the end of October 2016, the health plan The release of the new technical specifications for NIPT is an important milestone in the industry's standardization. Annoyouda spares no effort to promote the standardization process of the NIPT industry, and also hopes to promote the technology as a routine test in hospitals. Based on this, Annoyouda United Illumina has jointly developed the NextSeq 550AR, a next-generation sequencing machine designed for China's clinical design. Every step is carefully crafted and perfected. The approval of the NextSeq 550AR represents the entire industry on behalf of Annoyouda. The layout of the chain; on the other hand, it also marks the production of the most advanced high-throughput gene sequencer in China. Clinical application of NIPT to have a positive impact. "
Xi'an Double H Health Technology Co., Ltd , https://www.dhextract.com